Global /Australia /Healthcare /Drug Manufacturers - General /DXB

Dimerix Ltd.

DXB

• ASX: DXB • Delayed

0.2300AUD 7%

0.1641 USD

As of 6 June 2026, Dimerix Ltd. has a market cap of $92.12M USD, ranking #26131 globally and #608 in Australia. It ranks #2344 in the Healthcare sector, and #845 in the Drug Manufacturers - General industry.

Global Rank

26131

Country Rank

608

Sector Rank

2344

Industry Rank

845

Key Stats

Market Cap

$92.12MUSD

129.09M AUD

Enterprise Value

$64.68MUSD

90.63M AUD

Revenue (TTM)

$5.29MUSD

7.42M AUD

EBITDA (TTM)

-$28.75MUSD

-40.29M AUD

Net Income (TTM)

-$11.64MUSD

-16.31M AUD

Profit Margin

-220%

PS Ratio

17.4

PB Ratio

-76.8

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Nina Webster open_in_new

Employees

Website

dimerix.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
7%	-40%	-29%	-55%	-54%	-58%	-52%	137%	-12%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	DXB Dimerix Ltd ISIN: AU000000DXB7 Shares Out.: Shares Outstanding: 600.397M¹ Shares Float: 455.944M² TV: TradingView: ASX: DXB SA: Stock Analysis: ASX: DXB YF: Yahoo Finance: DXB.AX GF: Google Finance: ASX: DXB BA: Barron's: DXB MS: Morningstar: XASX: DXB	0.2300 AUD	TV: TradingView: ASX: DXB SA: Stock Analysis: ASX: DXB YF: Yahoo Finance: DXB.AX GF: Google Finance: ASX: DXB BA: Barron's: DXB MS: Morningstar: XASX: DXB
OTC Markets (OTCMKTS / OTC) MIC: OTCM	SBMJF Dimerix Ltd ISIN: AU000000DXB7 Shares Out.: Shares Outstanding: 588.437M¹ Shares Float: 416.179M² TV: TradingView: OTC: SBMJF SA: Stock Analysis: OTC: SBMJF YF: Yahoo Finance: SBMJF GF: Google Finance: OTCMKTS: SBMJF BA: Barron's: SBMJF MS: Morningstar: PINX: SBMJF	0.3500 USD	TV: TradingView: OTC: SBMJF SA: Stock Analysis: OTC: SBMJF YF: Yahoo Finance: SBMJF GF: Google Finance: OTCMKTS: SBMJF BA: Barron's: SBMJF MS: Morningstar: PINX: SBMJF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Dimerix Ltd.

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.

Similar Companies

Industry: Drug Manufacturers - General (Australia)

Name	Market Cap (USD) diff.	PE	Country
Sigma Healthcare Ltd. ASX: SIG	$22.82B 31.98B AUD 25K%	52.3	Australia
PYC Therapeutics Ltd. ASX: PYC	$926.22M 1.3B AUD 905%	-	Australia
Racura Oncology Ltd. ASX: RAC	$346.24M 485.18M AUD 276%	-	Australia
Clinuvel Pharmaceuticals Ltd. ASX: CUV	$335.4M 469.99M AUD 264%	14.5	Australia
Starpharma Holdings Ltd. ASX: SPL	$216.39M 303.23M AUD 135%	-	Australia
Mayne Pharma Group Ltd. ASX: MYX	$166.4M 233.18M AUD 81%	-	Australia

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 827K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 594K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 391K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 352K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 314K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 301K%	20.5	Switzerland

chevron_leftBack